The Danish pharmaceutical giant Novo Nordisk sees an increased sales, according to the company's latest report.
The turnover for the third quarter amounted to 71.3 billion Danish kronor, which can be compared to 68 billion kronor for the same period last year.
The company makes an operating profit of 33.8 billion Danish kronor. It was slightly higher than the analysts' expectations.
Novo Nordisk, which is the highest valued company in Europe, is world-leading in medicines for the treatment of diabetes and obesity.
